Literature DB >> 17181177

Design, synthesis, and evaluation of a potent, cell-permeable, conformationally constrained second mitochondria derived activator of caspase (Smac) mimetic.

Haiying Sun1, Zaneta Nikolovska-Coleska, Jianfeng Lu, Su Qiu, Chao-Yie Yang, Wei Gao, Jennifer Meagher, Jeanne Stuckey, Shaomeng Wang.   

Abstract

A potent, cell-permeable, conformationally constrained second mitochondria derived activator of caspase mimetic (SM-131, 2) has been designed, synthesized, and evaluated. Compound 2 binds to X-linked inhibitors of apoptosis proteins (XIAP) with a Ki of 61 nM in a competitive binding assay and directly antagonizes the XIAP inhibition of caspase-9 activity in a cell-free functional assay. Compound 2 achieves an IC50 of 100 nM in inhibition of cell growth and effectively induces cell death in the MDA-MB-231 human breast cancer cell line.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17181177     DOI: 10.1021/jm061108d

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  38 in total

1.  Smac mimetics increase cancer cell response to chemotherapeutics in a TNF-α-dependent manner.

Authors:  B L Probst; L Liu; V Ramesh; L Li; H Sun; J D Minna; L Wang
Journal:  Cell Death Differ       Date:  2010-04-30       Impact factor: 15.828

2.  Design, synthesis, and characterization of a potent, nonpeptide, cell-permeable, bivalent Smac mimetic that concurrently targets both the BIR2 and BIR3 domains in XIAP.

Authors:  Haiying Sun; Zaneta Nikolovska-Coleska; Jianfeng Lu; Jennifer L Meagher; Chao-Yie Yang; Su Qiu; York Tomita; Yumi Ueda; Sheng Jiang; Krzysztof Krajewski; Peter P Roller; Jeanne A Stuckey; Shaomeng Wang
Journal:  J Am Chem Soc       Date:  2007-11-14       Impact factor: 15.419

3.  Lipid-conjugated Smac analogues.

Authors:  Ewa D Micewicz; Josephine A Ratikan; Alan J Waring; Julian P Whitelegge; William H McBride; Piotr Ruchala
Journal:  Bioorg Med Chem Lett       Date:  2015-09-08       Impact factor: 2.823

4.  Autocrine TNFalpha signaling renders human cancer cells susceptible to Smac-mimetic-induced apoptosis.

Authors:  Sean L Petersen; Lai Wang; Asligul Yalcin-Chin; Lin Li; Michael Peyton; John Minna; Patrick Harran; Xiaodong Wang
Journal:  Cancer Cell       Date:  2007-11       Impact factor: 31.743

5.  Structure-based design, synthesis, evaluation, and crystallographic studies of conformationally constrained Smac mimetics as inhibitors of the X-linked inhibitor of apoptosis protein (XIAP).

Authors:  Haiying Sun; Jeanne A Stuckey; Zaneta Nikolovska-Coleska; Dongguang Qin; Jennifer L Meagher; Su Qiu; Jianfeng Lu; Chao-Yie Yang; Naoyuki G Saito; Shaomeng Wang
Journal:  J Med Chem       Date:  2008-11-27       Impact factor: 7.446

6.  Overcoming cancer therapy resistance by targeting inhibitors of apoptosis proteins and nuclear factor-kappa B.

Authors:  Yao Dai; Theodore S Lawrence; Liang Xu
Journal:  Am J Transl Res       Date:  2009-01-01       Impact factor: 4.060

7.  Novel SMAC-mimetics synergistically stimulate melanoma cell death in combination with TRAIL and Bortezomib.

Authors:  D Lecis; C Drago; L Manzoni; P Seneci; C Scolastico; E Mastrangelo; M Bolognesi; A Anichini; H Kashkar; H Walczak; D Delia
Journal:  Br J Cancer       Date:  2010-05-11       Impact factor: 7.640

8.  The SMAC mimetic BV6 induces cell death and sensitizes different cell lines to TNF-α and TRAIL-induced apoptosis.

Authors:  Mohamed El-Mesery; Mohamed E Shaker; Abdelaziz Elgaml
Journal:  Exp Biol Med (Maywood)       Date:  2016-07-28

9.  A Smac-mimetic sensitizes prostate cancer cells to TRAIL-induced apoptosis via modulating both IAPs and NF-kappaB.

Authors:  Yao Dai; Meilan Liu; Wenhua Tang; Yongming Li; Jiqin Lian; Theodore S Lawrence; Liang Xu
Journal:  BMC Cancer       Date:  2009-11-06       Impact factor: 4.430

10.  A small molecule inhibitor of XIAP induces apoptosis and synergises with vinorelbine and cisplatin in NSCLC.

Authors:  E J Dean; T Ward; C Pinilla; R Houghten; K Welsh; G Makin; M Ranson; C Dive
Journal:  Br J Cancer       Date:  2009-11-10       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.